Guggenheim starts 'CNS gene therapy pure-play' Taysha Gene Therapies at Buy 10:59 TSHA As reported before the open, Guggenheim analyst Debjit Chattopadyaya initiated coverage of Taysha Gene Therapies with a Buy rating and $28 price target. The central nervous system, or CNS, gene therapy "pure-play" is pursuing a single vector strategy for up to 26 monogenic, neuronal diseases that potentially could be corrected via intrathecally delivered AAV9. Chattopadyaya said regulatory clarity and clinical updates from up to four programs by year-end 2022 could validate the platform, making its current $400M enterprise value an attractive entry point given the 47% year-to-date decline in the shares.
> Sold off a lousy 50 shares of QURE before too much damage. Of course now the buying is happening. duh! This Taysha I didn't know it was gene therapy -
> Sold off a lousy 50 shares of QURE before too much damage. Of course now the buying is happening. duh! This Taysha I didn't know it was gene therapy -

